Ritchlin CT, et al. Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. ACR 2018, abstract L17.
Riociguat bij vroege diffuus cutane systemische sclerose: RISE-SSc
jan 2024 | ILD, Sclerodermie